Nevro (NVRO)
(Delayed Data from NYSE)
$4.92 USD
+0.09 (1.86%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $4.90 -0.02 (-0.41%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.92 USD
+0.09 (1.86%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $4.90 -0.02 (-0.41%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
Zacks News
What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.
What's in Store for SmileDirectClub's (SDC) Q4 Earnings?
by Zacks Equity Research
SmileDirectClub (SDC) is likely to have gained from a strong international presence in Q4.
Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?
by Zacks Equity Research
Consistent contribution from Henry Schein One is likely to have benefited Henry Schein's (HSIC) Q4 performance.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Trina Mukherjee
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Sonoco (SON) Meets Q4 Earnings Estimates
by Zacks Equity Research
Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.
Global Industrial Unit to Drive Ecolab's (ECL) Q4 Earnings
by Zacks Equity Research
Ecolab's (ECL) Q4 results are likely to reflect strength in core Global Industrial unit.
Medtronic (MDT) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.
Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?
by Zacks Equity Research
Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.
Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings
by Zacks Equity Research
Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter
What's in the Offing for LabCorp's (LH) Earnings in Q4?
by Zacks Equity Research
With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.
Here's Why You Should Hold on to Nevro (NVRO) Stock for Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results
by Zacks Equity Research
Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Nevro (NVRO) Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Nevro (NVRO) gains from several positive developments.
Why Is Nevro (NVRO) Up 9.6% Since Last Earnings Report?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FYC
Company News For Nov 8, 2019
by Zacks Equity Research
Companies In The News Are: GDDY, INSG, NVRO, TRIP
Nevro (NVRO) Q3 Loss Narrower Than Expected, Revenues Up Y/Y
by Zacks Equity Research
Nevro (NVRO) launches the Senza Omnia SCS System commercially in the United States in Q3.
Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 31.76% and 6.21%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Nevro (NVRO) Q3 Earnings Expected to Decline
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Nevro (NVRO) Stock for Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
Why Is Nevro (NVRO) Up 37.7% Since Last Earnings Report?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.